As Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, Mathai's mission is to focus the energy of the best research and development teams in the world at the intersection of profound unmet medical need and actionable breakthroughs in science and technology to make medicines of unequivocal benefit for humanity. The team works across a wide range of therapeutic areas and biological pathways. Janssen’s approach to medicines is patient-focused, agnostic to both source of the idea and the treatment modality. The team is invested deeply in data sciences in every aspect of R&D. Janssen R&D has fueled the growth of Janssen to be the largest pharmaceutical company in the United States, and the fourth largest in the world.
Prior to Janssen, Mathai was Senior Vice President at Merck Research Laboratories, and with his team initiated numerous new programs and progressed eight into early clinical development. At Theravance, a company he co-founded in 1997, his talented team nominated 31 development candidates in 17 years, created 4 approved products, and filed for a fifth.
Mathai has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his MD from Harvard Medical School/Massachusetts Institute of Technology and his PhD in Chemistry from Harvard.